Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
29%(2 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_3
3
38%
Ph phase_2
3
38%

Phase Distribution

2

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 23 (37.5%)
Phase 33 (37.5%)

Trials by Status

completed788%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

NCT03631407
completedphase_3

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)

NCT00474370
completedphase_1

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

NCT00766597
withdrawnphase_3

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

NCT00243568
completedphase_2

Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)

NCT00551330
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03631407Phase 2

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Completed
NCT00474370Phase 3

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)

Completed
NCT00766597Phase 1

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

Completed
NCT00243568Phase 3

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

Withdrawn
NCT00551330Phase 2

Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)

Completed
NCT00523211Phase 3

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)

Completed
NCT00632073Phase 1

Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)

Completed
NCT00551018Phase 2

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8